Global Antibody and Recombinant Protein CDMO Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
According to MRAResearch’s new survey, global Antibody and Recombinant Protein CDMO market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antibody and Recombinant Protein CDMO market research.
Key companies engaged in the Antibody and Recombinant Protein CDMO industry include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Antibody and Recombinant Protein CDMO were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Antibody and Recombinant Protein CDMO market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Antibody and Recombinant Protein CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Cerbios-Pharma SA
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Segment by Type
Antibody CDMO
Recombinant Protein CDMO
Pharmaceutical Company
Biotechnology Company
Generic Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Antibody and Recombinant Protein CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Key companies engaged in the Antibody and Recombinant Protein CDMO industry include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Antibody and Recombinant Protein CDMO were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Antibody and Recombinant Protein CDMO market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Antibody and Recombinant Protein CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Cerbios-Pharma SA
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Segment by Type
Antibody CDMO
Recombinant Protein CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Generic Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Antibody and Recombinant Protein CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source